Naxitamab Added to Induction for Newly Diagnosed High-Risk Neuroblastoma
Recruiting · Phase 2 · NCT05489887
Conditions: Neuroblastoma
At a glance
- Research payments reported, 2025
- $9,100
- U.S. investigators named
- 1
- Sites paid
- 1
- Planned or actual enrollment
- 93
About the trial
- Sponsor
- Giselle Sholler (with Y-mAbs Therapeutics)
- Tested
- Naxitamab (drug)
- Dates
- Started 2022-09-14; completion 2036-09
- Results posted
- Not yet
This is a prospective, multicenter clinical trial in subjects with newly diagnosed high-risk neuroblastoma to evaluate the efficacy and safety of administering naxitamab with standard induction therapy. The initial chemotherapy will include 5 cycles of multi-agent chemotherapy. Naxitamab will be added to all 5 Induction cycles. We hypothesize that the addition of anti-GD2 therapy to induction chemotherapy will result in improved end of induction responses and improved survival.
From ClinicalTrials.gov, last updated 2026-08-12. Full record, eligibility and contacts (opens in a new tab)
Industry funding
Caris Mpi, Inc. reported $9,100 in research payments for this study in 2025 (7 payments).
Research payments usually go to hospitals, universities and research sites to run a study, not to the investigators personally. A payment is not evidence of wrongdoing.
U.S. investigators named on this study
Clinicians the company named as principal investigators in its Open Payments reports.
Sites paid to run it
- The Pennsylvania State University $9,100
Sources: CMS Open Payments research payments (program year 2025) and ClinicalTrials.gov, U.S. National Library of Medicine.